News
The phase 2B SURVIVE trial testing SurVaxM, a cancer vaccine for glioblastoma, will continue as planned following an interim analysis showing sufficient promise to proceed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback